{
  "main_header": {
    "sid": 1002605,
    "name": "Fredun Pharma",
    "stock_name": "Fredun Pharma",
    "full_name": "Fredun Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/fredun-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "654.95",
    "chg": 9.85,
    "chgp": "1.53%",
    "dir": 1,
    "prev_price": "645.10",
    "mcapval": "309.25 Cr",
    "mcap": "Micro Cap",
    "scripcode": 539730,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE194R01017",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "01:24 AM",
    "bse_nse_vol": "3.59 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/fredun-pharma-1002605-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Fredun Pharmaceuticals Reports Strong Sales Growth Amid Ongoing Market Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/fredun-pharmaceuticals-reports-q3-fy24-25-sales-growth-of-26-87-amid-stock-downgrade-751369",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/FredunPharmaceu_mojoScore_370265.png",
        "date": "2025-02-05 18:55:03",
        "description": "Fredun Pharmaceuticals has recently experienced an evaluation adjustment reflecting its current market dynamics. The company reported significant growth in net sales and operating profit, with positive results over the last three quarters. However, it has struggled against benchmark indices, leading to a complex financial situation."
      },
      {
        "title": "Fredun Pharmaceuticals Reports Strong Q3 FY24-25 Growth Amid Rising Interest Costs",
        "link": "https://www.marketsmojo.com/news/result-analysis/fredun-pharmaceuticals-reports-24-3-sales-growth-and-26-3-pat-increase-in-q3-fy24-25-746063",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/FredunPharmaceu_quaterlyResult_354441.png",
        "date": "2025-02-05 09:37:13",
        "description": "Fredun Pharmaceuticals has announced its financial results for the quarter ending December 2024, highlighting a year-on-year increase in net sales and profit before tax. The profit after tax reached a five-quarter high, while earnings per share also improved. However, rising interest costs indicate increased borrowings."
      },
      {
        "title": "Fredun Pharmaceuticals Reports Strong Q2 FY24-25 Growth Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/fredun-pharmaceuticals-reports-26-87-net-sales-growth-in-q2-fy24-25-4-749602",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/FredunPharmaceu_mojoScore_335407.png",
        "date": "2025-02-03 18:39:44",
        "description": "Fredun Pharmaceuticals has recently adjusted its evaluation, highlighting its financial performance in the pharmaceuticals sector. The company reported significant growth in net sales and operating profit for Q2 FY24-25, with notable increases in profit after tax and operational efficiency, despite a challenging year."
      }
    ],
    "total": 24,
    "sid": "1002605",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/fredun-pharmaceuticals-1002605"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "09-Apr-2025",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Fredun Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24239MH1987PLC043662</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: JINKAL SHAH <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICIER <br/> EmailId: CS@FREDUNGROUP.COM</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: FREDUN MEDHORA <br/> Designation: CFO AND MD <br/> EmailId: FREDUN@FREDUNGROUP.COM</div> </div> <div> <br/> Date: 09/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "09-Apr-2025",
      "details": "The company has secured a tender from Tamil Nadu Medical Services Corporation (TNMSC) for the supply of generic medicinesvalued between Rs.150 million and Rs. 180 million",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)",
      "datetime": "03-Apr-2025",
      "details": "Announcement regarding upgradation of ratings assigned to its bank facilities by Infomerics Valuation and Rating Ltd.The upgrade reflects the companys strong financial performance and operational resilence.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Fredun Pharmaceuticals Ltd has declared <strong>7%</strong> dividend, ex-date: 23 Sep 24",
          "dt": "2024-09-23",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Fredun Pharmaceuticals Reports Strong Sales Growth Amid Ongoing Market Challenges

2025-02-05 18:55:03

Fredun Pharmaceuticals has recently experienced an evaluation adjustment reflecting its current market dynamics. The company reported significant growth in net sales and operating profit, with positive results over the last three quarters. However, it has struggled against benchmark indices, leading to a complex financial situation.

Read More

Fredun Pharmaceuticals Reports Strong Q3 FY24-25 Growth Amid Rising Interest Costs

2025-02-05 09:37:13

Fredun Pharmaceuticals has announced its financial results for the quarter ending December 2024, highlighting a year-on-year increase in net sales and profit before tax. The profit after tax reached a five-quarter high, while earnings per share also improved. However, rising interest costs indicate increased borrowings.

Read More

Fredun Pharmaceuticals Reports Strong Q2 FY24-25 Growth Amid Market Challenges

2025-02-03 18:39:44

Fredun Pharmaceuticals has recently adjusted its evaluation, highlighting its financial performance in the pharmaceuticals sector. The company reported significant growth in net sales and operating profit for Q2 FY24-25, with notable increases in profit after tax and operational efficiency, despite a challenging year.

Read More

View All News